Panel · Use case · Innovation

DTx Coverage Divergence.

LiveDivergence Review

Map where specialists disagree on whether the evidence for a prescription digital therapeutic is enough for payer coverage.

QuestionIs the evidence enough for payer coverage?

DisciplinesDigital therapeutics, HEOR, evidence, regulatory

ReaderDigital health and access leads

Not askedA price

DepthStandard, four seats

DTx Coverage Divergence is a ready-made use case for Innovation. It ships under the Divergence Review template.

For digital health and market access leads. You get each seat's answer to the same question, where the positions diverge, whether each split is evidence, assumption or value, the cruxes and what would settle it. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Is the evidence base for a prescription digital therapeutic sufficient to support payer coverage?

Who is at the table

Payers have no common standard for software. Germany’s fast track allows provisional listing with evidence to follow, and NICE tiers software by risk. The seats may disagree on which standard applies.

Seat	What it is asked	What it works from
Head of Digital Therapeutics	Whether the trials show clinical benefit and the engagement needed for it.^{1Digital Therapeutics Alliance. Understanding DTx.}	Trial reports and the Alliance’s definitions.
HEOR Evidence Lead	What a payer would call sufficient and where the product falls short.^{2National Institute for Health and Care Excellence. Evidence standards framework (ESF) for digital health technologies.,3Federal Institute for Drugs and Medical Devices (BfArM). Digital Health Applications (DiGA): Interesting facts. DiGA Guide version 3.6.}	The NICE framework and the DiGA directory.
Global Value & Evidence Lead	How certain the effect is and how well it generalizes.	Systematic reviews of software interventions.
Regulatory Strategist	Whether the clearance supports the claims a payer will weigh.	The product’s clearance.

What the review does

Which standard applies is itself a dispute. A provisional listing with evidence to follow and a requirement for high-certainty benefit are different standards. The review shows which seat uses which.^{2National Institute for Health and Care Excellence. Evidence standards framework (ESF) for digital health technologies.,3Federal Institute for Drugs and Medical Devices (BfArM). Digital Health Applications (DiGA): Interesting facts. DiGA Guide version 3.6.}

Engagement is the quiet crux. Whether benefit depends on how much patients use the software is a fact that trials measure inconsistently. The review marks where the seats diverge on it.^{1Digital Therapeutics Alliance. Understanding DTx.}

What would settle it. A named analysis of benefit by level of use, or a payer pilot with agreed outcomes.

Recommended length

Standard

Four disciplines will read this question differently. Standard depth types each divergence as evidence, assumption or value in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the review checks

The review states the assumptions each position relies on, and says what each gap limits. Examples for this question:

Trial participants resemble the patients a payer covers.
Benefit seen at six months lasts.
A payer will treat the product as a drug-like benefit and not as a device.

Standards, guidance and sources

Frame

Digital Therapeutics Alliance, Understanding DTx.^{1Digital Therapeutics Alliance. Understanding DTx.}
NICE, Evidence Standards Framework for digital health technologies.^{2National Institute for Health and Care Excellence. Evidence standards framework (ESF) for digital health technologies.}
BfArM, DiGA directory and fast-track process.^{3Federal Institute for Drugs and Medical Devices (BfArM). Digital Health Applications (DiGA): Interesting facts. DiGA Guide version 3.6.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any claim that a payer in one country sets the standard for another, any benefit measured without usage data, and any result from one trial.

What arrives

The question as put
The shape of the disagreement
Each position, in its own terms
Where they diverge
Why they diverge: evidence, assumption or value
The cruxes
What would settle it

What it will not do

It does not force a consensus, and it is a deliberation of AI specialists and not a vote of human experts. The decision stays with you.

It does not decide coverage or set a price.

It does not force a consensus. A report that closes every gap would be the wrong output.

It is not a vote of human experts. Every seat is an AI specialist, and the report says so.

It does not name a winner. It says what would settle the question and leaves the decision to you.

References

[1] Digital Therapeutics Alliance. Understanding DTx. Read on 9 October 2026.
[2] National Institute for Health and Care Excellence. Evidence standards framework (ESF) for digital health technologies. Not read in full.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Digital Health Applications (DiGA): Interesting facts. DiGA Guide version 3.6. Read on 9 October 2026.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.